Remarkable regression of massive deep vein thrombosis in response to intensive oral rivaroxaban treatment

Thrombosis Journal

Volumn 13, Issue 1, 2015, Pages

  Koitabashi, Norimichi ^a   Niwamae, Nogiku ^b   Taguchi, Tetsuya ^c   Ohyama, Yoshiaki ^a   Takama, Noriaki ^a   Kurabayashi, Masahiko ^a  

^a GUNMA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b MAEBASHI RED CROSS HOSPITAL   (Japan)

^c Fukaya Red Cross Hospital   (Japan)

Author keywords

Anticoagulation; Deep vein thrombosis; Iliac vein compression; Rivaroxaban; Thrombus regression

Indexed keywords

D DIMER; HEPARIN; PREDNISOLONE; RIVAROXABAN;

ABDOMINAL AORTA; AGED; ANTICOAGULANT THERAPY; ARTICLE; BLOOD LEVEL; CASE REPORT; COLOR ULTRASOUND FLOWMETRY; DRUG DOSE REDUCTION; FEMORAL VEIN; HEAT SENSATION; HUMAN; ILIAC VEIN; INFERIOR CAVA VEIN; INTENSIVE CARE; INTRAVASCULAR ULTRASOUND; LEG EDEMA; LEG PAIN; LEG SWELLING; LEG VEIN; LOWER EXTREMITY DEEP VEIN THROMBOSIS; LOWER LEG; LUMBAR VERTEBRA; MALE; MULTIDETECTOR COMPUTED TOMOGRAPHY; POPLITEAL VEIN; REMISSION; RHEUMATIC POLYMYALGIA; SKIN REDNESS; TREATMENT DURATION; TREATMENT RESPONSE; VEIN BLOOD FLOW; VEIN MALFORMATION;

EID: 84925041561     PISSN: None     EISSN: 14779560     Source Type: Journal    
DOI: 10.1186/s12959-015-0045-1     Document Type: Article

References (24)

1. Goldhaber SZ, Bounameaux H. Pulmonary embolism and deep vein thrombosis. Lancet. 2012;379:1835-46.
2. Augustinos P, Ouriel K. Invasive approaches to treatment of venous thromboembolism. Circulation. 2004;110:I27-34.
3. Konstantinides SV, Torbicki A, Agnelli G, Danchin N, Fitzmaurice D, Galie N, et al. 2014 esc guidelines on the diagnosis and management of acute pulmonary embolism: The task force for the diagnosis and management of acute pulmonary embolism of the european society of cardiology (esc)endorsed by the european respiratory society (ers). Eur Heart J. 2014;35:3033-73.
4. Buller HR, Prins MH, Lensin AW, Decousus H, Jacobson BF, Minar E, et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012;366:1287-97.
5. Schirmer SH, Baumhakel M, Neuberger HR, Hohnloser SH, van Gelder IC, Lip GY, et al. Novel anticoagulants for stroke prevention in atrial fibrillation: Current clinical evidence and future developments. J Am Coll Cardiol. 2010;56:2067-76.
6. Galanis T, Keiffer G, Merli G. The new oral anticoagulants for the treatment of venous thromboembolism: A new paradigm shift in antithrombotic therapy. Curr Ther Res Clin Exp. 2014;76:76-83.
7. Castellucci LA, Cameron C, Le Gal G, Rodger MA, Coyle D, Wells PS, et al. Clinical and safety outcomes associated with treatment of acute venous thromboembolism: A systematic review and meta-analysis. JAMA. 2014;312:1122-35.
8. Agnelli G, Gallus A, Goldhaber SZ, Haas S, Huisman MV, Hull RD, et al. Treatment of proximal deep-vein thrombosis with the oral direct factor xa inhibitor rivaroxaban (bay 59-7939): The odixa-dvt (oral direct factor xa inhibitor bay 59-7939 in patients with acute symptomatic deep-vein thrombosis) study. Circulation. 2007;116:180-7.
9. Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H, Gallus AS, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010;363:2499-510.
10. Yamada N, Hirayama A, Maeda H, Sakagami S, Shikata H, Prins MH, et al. Oral rivaroxaban for Japanese patients with symptomatic venous thromboembolism - the J-EINSTEIN DVT and PE program. Thromb J. 2015;13:2.
11. Brazeau NF, Harvey HB, Pinto EG, Deipolyi A, Hesketh RL, Oklu R. May-thurner syndrome: Diagnosis and management. Vasa. 2013;42:96-105.
12. Fazel R, Froehlich JB, Williams DM, Saint S, Nallamothu BK. Clinical problem-solving. A sinister development-a 35-year-old woman presented to the emergency department with a 2-day history of progressive swelling and pain in her left leg, without antecedent trauma. N Engl J Med. 2007;357:53-9.
13. Liu Z, Gao N, Shen L, Yang J, Zhu Y, Li Z, et al. Endovascular treatment for symptomatic iliac vein compression syndrome: A prospective consecutive series of 48 patients. Ann Vasc Surg. 2014;28:695-704.
14. Kibbe MR, Ujiki M, Goodwin AL, Eskandari M, Yao J, Matsumura J. Iliac vein compression in an asymptomatic patient population. J Vasc Surg. 2004;39:937-43.
15. Goldhaber SZ, Meyerovitz MF, Green D, Vogelzang RL, Citrin P, Heit J, et al. Randomized controlled trial of tissue plasminogen activator in proximal deep venous thrombosis. Am J Med. 1990;88:235-40.
16. Kanter DS, Mikkola KM, Patel SR, Parker JA, Goldhaber SZ. Thrombolytic therapy for pulmonary embolism. Frequency of intracranial hemorrhage and associated risk factors. Chest. 1997;111:1241-5.
17. Meyer G, Vicaut E, Danays T, Agnelli G, Becattini C, Beyer-Westendorf J, et al. Fibrinolysis for patients with intermediate-risk pulmonary embolism. N Engl J Med. 2014;370:1402-11.
18. Comerota AJ, Aldridge SC. Thrombolytic therapy for deep venous thrombosis: A clinical review. Can J Surg. 1993;36:359-64.
19. van Ramshorst B, van Bemmelen PS, Hoeneveld H, Faber JA, Eikelboom BC. Thrombus regression in deep venous thrombosis. Quantification of spontaneous thrombolysis with duplex scanning. Circulation. 1992;86:414-9.
20. Khalafallah AA, Renu S, Sharp C, Hannan T. Extensive venous thrombosis in a healthy young man with a short inferior vena cava syndrome treated successfully with rivaroxaban. BMJ Case Rep. 2012; doi:10.1136/bcr-2012-007313.
21. Hammerstingl C, Potzsch B, Nickenig G. Resolution of giant left atrial appendage thrombus with rivaroxaban. Thromb Haemost. 2013;109:583-4.
22. Takasugi J, Yamagami H, Okata T, Toyoda K, Nagatsuka K. Dissolution of the left atrial appendage thrombus with rivaroxaban therapy. Cerebrovasc Dis. 2013;36:322-3.
23. Pannach S, Babatz J, Beyer-Westendorf J. Successful treatment of acute portal vein thrombosis with rivaroxaban. Thromb Haemost. 2013;110:626-7.
24. Varin R, Mirshahi S, Mirshahi P, Klein C, Jamshedov J, Chidiac J, et al. Whole blood clots are more resistant to lysis than plasma clots-greater efficacy of rivaroxaban. Thromb Res. 2013;131:e100-9.